Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE neoadjuvant nivolumab with or without ipilimumab in advanced cutaneous squamous cell carcinoma
2020-001074-30Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Histopathological tumor response after neoadjuvant immune checkpoint inhibition. Started May 2020; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2020-001074-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001074-30.